Rhythm (RYTM) news

Rhythm's Incivree launches in Japan for hypothalamic obesity

Rhythm Pharmaceuticals, Inc. has announced the launch of its drug Incivree (setmelanotide) in Japan for the treatment of hypothalamic obesity. This marks a significant expansion of the medication’s availability, following its approval by Japanese regulatory authorities. Hypothalamic obesity is a…

Rhythm Pharmaceuticals, Inc.: H.C. Wainwright raises target price to $130 from $105

H.C. Wainwright has raised its target price for Rhythm Pharmaceuticals, Inc. (RYTM) to $130 from $105, reflecting a positive reassessment of the company’s outlook . This adjustment aligns with a broader trend of analysts increasing their price targets for RYTM, with recent updates ranging from $92…

Rhythm Biosciences - Appoints Sue MacLeman as interim chair effective immediately

Rhythm Biosciences has announced the appointment of Sue MacLeman as interim chair of the board, effective immediately. This decision follows a strategic review of the company’s leadership structure and aims to ensure continuity during a period of transition. MacLeman brings extensive experience in…

Rhythm Biosciences - Gavin Fox-Smith resigns as chair and non-executive director effective immediately

Gavin Fox-Smith has resigned as chair and non-executive director of Rhythm Biosciences, effective immediately, the company announced in a regulatory filing. No specific reason for the resignation was disclosed in the statement. Fox-Smith, who has served in the role since 2021, will no longer…

Rhythm Pharma gets Canada weight management nod for Incivree